Jacob Sindhu, Al-Kandari Asmaa, Alroughani Raed, Al-Temaimi Rabeah
Molecular Pathology Unit, Department of Pathology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat, 13110 Jabriya, Kuwait.
Department of Pathology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat, 13110 Jabriya, Kuwait.
J Neuroimmunol. 2017 Apr 15;305:5-8. doi: 10.1016/j.jneuroim.2017.01.008. Epub 2017 Jan 13.
In a cross-sectional study involving 160 Multiple Sclerosis (MS) patients and 70 healthy controls we set out to determine the association of five blood biomarkers with MS risk and progression scores. High levels of Semaphorin3A (SEMA3A) in females, and low levels of prolactin and estradiol in males associated with MS risk. High MS disability correlated with higher SEMA3A levels in females. Our findings suggest the clinical applicability of SEMA3A, and prolactin as biomarkers for MS progression. However, these biomarkers had sex-specific associations with MS, and any therapeutic approaches utilizing them should take that into consideration.
在一项涉及160名多发性硬化症（MS）患者和70名健康对照者的横断面研究中，我们着手确定五种血液生物标志物与MS风险及进展评分之间的关联。女性中高水平的信号素3A（SEMA3A）以及男性中低水平的催乳素和雌二醇与MS风险相关。MS高残疾程度与女性中较高的SEMA3A水平相关。我们的研究结果表明SEMA3A和催乳素作为MS进展生物标志物具有临床适用性。然而，这些生物标志物与MS存在性别特异性关联，任何利用它们的治疗方法都应考虑到这一点。
